Re: Wells Et Al.: Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results From a Comparative Effectiveness Randomized Clinical Trial (Ophthalmology 2016;123:1351-1359)

Ophthalmology- Netherlands

doi 10.1016/j.ophtha.2016.03.052

Full Text

Abstract

Available in

Categories

Ophthalmology

Date

Authors

Publisher

Elsevier BV

Related search

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

Ophthalmology
Ophthalmology
2016English

Comparative Effectiveness Trial for Diabetic Macular Edema

JAMA Ophthalmology
Ophthalmology
2015English

Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Ophthalmology
Ophthalmology
2015English

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

Acta Ophthalmologica
MedicineOphthalmology
2010English

Re: Das Et Al.: Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets (Ophthalmology 2015;122:1375-94)

Ophthalmology
Ophthalmology
2016English

Pss34 - Cost-Effectiveness of Intravitreal Aflibercept Versus Ranibizumab in the Treatment of Diabetic Macular Edema in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema

American Journal of Ophthalmology
Ophthalmology
2016English

Re: Feuer Et Al.: Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results (Ophthalmology 2016;123:558-70)

Ophthalmology
Ophthalmology
2016English

Re: Merani Et Al.: Aqueous Chlorhexidine for Intravitreal Injection Antisepsis ( Ophthalmology. 2016;123:2588-2594)

Ophthalmology
Ophthalmology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy